Icell Kealex Therapeutics is a pharmaceutical start-up based in JLabs-TMC in Houston and has integrated T-cell based immunotherapy into an oncolytic virus, enhancing the immune response against solid tumors.
Icell Kealex Therapeutics was founded by scientists from Baylor College of Medicine. The company joined Johnson and Johnson innovations at Jlabs-TMC in January 2016 to start the development and clinical trials of the oncolytic vaccinia virus therapy.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Icell Kealex Therapeutics have combined vaccinia virus with T-cell based immunotherapy, arming it with T-cell engagers, creating T-cell engager-armed oncolytic vaccinia virus (TEA-VV). The foremost perk of TEA-VV is its ability to kill tumor cells not infected with the virus, further TEA-VV specifically induces antitumor immunity without activating the part of the immune system responsible for initiating viral clearance.
Recover your password.
A password will be e-mailed to you.